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RET receptor tyrosine kinase (RTK) is a driver oncogene in human cancer. We recently 
identified the clinical drug candidate Pz-1, which targets RET and VEGFR2. A key in vivo 
metabolite of Pz-1 is its less active demethylated pyrazole analogue. Using bioisosteric 
substitution methods, here, we report the identification of NPA101.3, lacking the structural 
liability for demethylation. NPA101.3 showed selective inhibitory profile and an inhibitory 
concentration 50 (IC50) of <0.001 µM for both RET and VEGFR2. NPA101.3 inhibited 
phosphorylation of all tested RET oncoproteins as well as VEGFR2 and proliferation of cells 
transformed by RET. Oral administration of NPA101.3 (10 mg/kg/day) completely prevented 
formation of tumours induced by RET/C634Y-transformed cells, while it decreased, but did 
not abrogate, formation of tumours induced by a control oncogene (HRAS/G12V). The 
balanced synchronous inhibition of both RET and VEGFR2, as well the resistance to 
demethylation, renders NPA101.3 a potential clinical candidate for RET-driven cancers. 
 4 
INTRODUCTION 
RET (REarranged during Transfection) is the receptor tyrosine kinase (RTK) for neurotrophic 
factors of the GDNF (glial cell line-derived neurotrophic factor) family (1). In several human 
cancers, RET rearrangements lead to the formation of chimeric oncoproteins, containing the 
RET tyrosine-kinase (TK) domain fused to the N-terminal region of heterologous proteins. 
These include: papillary thyroid carcinoma (PTC) (2), medullary thyroid carcinoma (MTC) 
(3), lung adenocarcinoma (4-6), chronic myeloproliferative disorders (7, 8), Spitz melanoma 
(9), colon (10, 11), breast (12) and salivary duct (13) carcinomas. CCDC6-RET rearrangement 
has also been found in EGFR mutant lung adenocarcinoma patients who had progressed upon 
EGFR TKI treatment (14). In addition, various types of germline point mutations activating 
the RET kinase are the causative event of hereditary MTC, in the frame of multiple endocrine 
neoplasia type 2 (MEN2A, MEN2B) syndromes. Somatic RET mutations, mostly 
RET/M918T, are commonly associated (around 50% of cases) to sporadic MTC (1, 15). 
Finally, RET is overexpressed in several malignancies including breast (16, 17) and pancreatic 
(18, 19) carcinoma.  
RET targeting with tyrosine kinase inhibitors (TKIs) has emerged as a promising 
molecular approach for the treatment of cancer (20, 21). Two TKIs, Vandetanib and 
Cabozantinib, were found to exhibit VEGFR2 and RET activity (22, 23). These two drugs 
have been approved to treat MTC because of their capability to prolong progression-free 
survival (24, 25). In addition, Sorafenib and Lenvatinib, two multikinase inhibitors with 
activity against RET, have been approved for the treatment of radioiodine-refractory 
differentiated thyroid cancer (26, 27). Novel TKIs, BLU-667, LOXO-292 and RXDX-105, 
have recently demonstrated promising clinical activity in RET-driven cancers (28-30). 
Toxicity, due to on- or off-targets effects, and resistance formation may limit efficacy 
of TKIs in clinical practice. We sought out to set up a fragment-based chemical screen to 
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identify novel RET inhibitors. This approach lead to the clinical candidate Pz-1, a type-2 TKI 
directed against RET and VEGFR2 (31).  
In vivo stability is a critical factor that directly determines efficacy (32). Through 
completion of investigative new drug (IND) studies, a demethylated less active metabolite of 
Pz-1 was identified. Here, by applying bioisosteric substitution of the Pz-1 site susceptible to 
demethylation, we report the identification of NPA101.3, as a novel clinical TKI candidate 




Discovery of NPA101.3. During IND-studies of Pz-1, a series of in vivo metabolites were 
identified; via Phase 1 metabolic systems, Pz-1 is oxidized, hydrolysed, or demethylated 
generating a less active derivative (Fig. 1 and data not shown). Hydrolysis and initial oxidation 
occur at the selectivity region, which is the region of Pz-1 that enters the allosteric pocket of 
both RET and VEGFR2. Any modification to reduce metabolism at this region can alter 
selectivity and inhibitory profiles and, therefore is likely to alter the optimized RET/VEGFR2 
inhibitory profile. Another major, metabolic pathway of Pz-1 is initiated via the Phase 1 
demethylation of methylpyrazole to generate Pz-1a. In turn, Pz-1a is further biotransformed 
via oxidation (to Pz-1b) or oxidation and sugar conjugation through Phase 2 systems (to Pz-
1c). Interestingly, the methylpyrazole substituent of Pz-1 is oriented towards the solvent and 
is not expected to contribute significantly to selectivity profiles (31, 32) (Fig. 1).  
Bioisosteric replacement of the methylpyrazole of Pz-1 was investigated to generate 
an alternative clinical candidate with similar polypharmacological profile but resistance to 
demethylation. In both RET and VEGFR2, the methylpyrazole binds to solvent exposed 
regions, which can accommodate a variety of substituents. SAR studies have shown that 
replacement of methylpyrazole with various five-member ring systems decreases inhibitory 
activity (31). Therefore, substitution with polar, electron-deficient (methylsulfonyl)benzene 
was investigated. The methylsulfonyl group occupies the same chemical space as the methyl 
pyrazole and has the same hydrogen binding pattern at the computer modelling (data not 
shown); therefore, it is expected not to affect the pharmacological activity of the drug as 
compared to methylpyrazole. Importantly, analogues containing (methylsulfonyl)benzene do 
not carry the structural liability of demethylation. Therefore, the (methylsulfonyl)benzene was 
chosen as an appropriate bioisosteric replacement for methylpyrazole, to obtain the novel 
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compound designated NPA101.3 (Fig. 1). The chemical synthesis of NPA101.3 is described 
in the Supplementary information. 
 
Computational modelling of NPA101.3. NPA101.3 was modelled in the RET kinase DFG 
(aspartic acid [D892], phenylalanine [F893], glycine [G894])-out computational model as 
previously described (Fig. 2) (31). The model suggested that NPA101.3 binds to RET kinase 
in its inactive (DFG-out) conformation, as it is characteristic of type-2 TKIs (33). The 
benzimidazole moiety acts as the ‘warhead’, making a key hydrogen bond with A807 at the 
RET ATP binding site (hinge-region). The benzimidazole also forms two π-π stacking 
interactions with Y806. The p-sulfone substituent displays orientation towards the solvent and 
engages K728 through a cation-π interaction. The amide region interacts with D892 from the 
DFG motif through a hydrogen bond. This interaction opens-up a novel lipophilic pocket, 
which is effectively filled by tert-butyl isoxazole. The modelling predicted NPA101.3 to bind 
RET with high affinity and with a projected ΔG of -11.4 k/cal mol. Moreover, the model 
indicated that binding of NPA101.3 was not influenced by substitutions of V804, which is the 
gatekeeper residue whose replacement with a methionine or a leucine confers resistance to 
Vandetanib, Cabozantinib, and several other inhibitors (Fig. 2) (29, 34-36). NPA101.3 was 
also predicted to bind VEGFR2 with comparable high affinity (Fig. 2). Indeed, similar to Pz-
1, the free rotation of the methylene linker permits tailored orientation of the isoxazole in the 
allosteric pocket of both RET and VEGFR2 enabling balanced inhibition of both kinases (31).  
 
Kinase inhibitory activity of NPA101.3. We tested the ability of NPA101.3 to inhibit RET, 
the RET/V804M mutant, and VEGFR2 in an in vitro kinase assay. To determine if NPA101.3 
tightly bound the kinase, we used high concentration of ATP (190 µM). Such a high 
concentration is orders of magnitude greater than the Km for either RET or VEGFR2 and 
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reflects the high intracellular concentration of ATP (1-10 mM). NPA101.3 exhibited an 
inhibitory concentration 50 (IC50) of 0.001 µM for RET, 0.008 µM for RET/V804M, and 
0.003 µM for VEGFR2. Thus, NPA101.3 represents a novel RET/VEGFR2 dual inhibitor 
with a pharmacological profile similar to Pz-1. 
 To further investigate NPA101.3 binding to RET, a thermal shift assay was performed 
to monitor protein melting temperature. This assay determines the drug-induced increase in 
the melting temperature (ΔTm) of the isolated RET kinase domain, which reflects the stability 
of the kinase-ligand complex (37, 38) and correlates with the inhibitor IC50 (39). Addition of 
NPA101.3 increased the thermal stability of active and phosphorylated RET by a dramatic 
ΔTm of 16 °C ± 1.1 °C, over a time course of 240 minutes (Fig. 3C; a representative 
experiment is reported in Fig. 3A). This was consistent with values seen for type-2 inhibitors, 
such as Sorafenib, stabilising a DFG-out inactive conformer (40). We observed the same 
magnitude of thermal shift by NPA101.3 for wild type and V804M (Fig. 3B), confirming that 
the compound is insensitive to gatekeeper mutation. In contrast, a substantially smaller ΔTm 
shift of 6.1°C ± 3.3 °C was observed with the type-1 compound PP1 (Fig. 3C), consistent with 
our previous published data (38). As expected, the type-1 inhibitor PP1 was sensitive to 
gatekeeper mutation (Fig. 3C). We conclude that NPA101.3 binds tightly to both wild type 
and V804M RET kinase domain in a type-2 binding mode. 
 Finally, NPA101.3, at a concentration of 100 nM, was subjected to a kinome scan 
against a 96 kinases panel representing major kinome clusters (Supplementary Information, 
Table S1). The compound featured good selectivity, displaying strong binding activity (>90% 
bound) for only 7 additional kinases (CSF1R, FRK, HCK, LYN, MKNK2, TRKA, and 
TRKC) and weak binding (>10-35% bound) for another 6 kinases (Supplementary 
information Table S1 and Fig. S1). It is important to note that measurement of binding affinity, 
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that is based on control-ligand displacement (Kd), is more sensitive than the in vitro kinase 
assay. In conclusion, NPA101.3 represents a highly selective type-2 kinase inhibitor. 
 
NPA101.3-mediated inhibition of RET and VEGFR2 phosphorylation and signalling.  
Fibroblasts transfected with RET/C634R were treated with increasing doses of NPA101.3, 
ranging from 0.1 to 10.0 nM. RET autophosphorylation was assessed by Western blotting 
using two different antibodies able to recognize phosphorylated Y905, located in the RET 
kinase activation loop, or Y1062, a multidocking site involved in RET downstream signalling 
(41). As shown in Figure 4A, RET phosphorylation started to be inhibited at 0.3 nM and was 
almost completely blocked at 3.0 nM. NPA101.3 also inhibited other MTC-associated RET 
oncogenic point mutants, including RET/M918T, RET/A883F, and RET/V804L/M (Fig. 4B). 
Rearranged RET oncoproteins (CCDC6-RET, NCOA4-RET, FGFR1OP-RET) were highly 
sensitive to NPA101.3 inhibition, as well (Fig. 4C). Finally, 1.0 nM NPA101.3 reduced 
ligand-induced VEGFR2 autophosphorylation; inhibition was virtually total at 10.0 nM, 
indicating that NPA101.3 has similar inhibitory activity for VEGFR2 and RET (Fig. 4D). 
 NPA101.3 inhibited RET autophosphorylation and signalling along the SHC/MAPK 
pathway in human cancer cell lines endogenously expressing RET oncogenic variants, 
including MTC cell lines, TT (RET/C634W) and MZ-CRC-1 (RET/M918T), PTC cell line 
TPC-1 (CCDC6-RET); in the lung adenocarcinoma cell line Lc-2/ad (CCDC6-RET) only 
RET and SHC (but not MAPK) de-phosphorylation was detectable (Supplementary 
information, Fig. S2). Virtually no effect on SHC/MAPK signalling was identified in control 
cell lines lacking RET oncogenes, including Nthy-ori-3.1 thyroid follicular cells, BCPAP and 
8505-C, derived from thyroid cancers negative for RET oncogenes, and PC-9, A549 and 
CALU-1, derived from lung adenocarcinomas negative for RET oncogenes (Supplementary 
information, Fig. S3). 
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NPA101.3-mediated inhibition of RET-driven cell proliferation. The murine pro–B cell 
line Ba/F3 requires IL-3 for proliferation and survival; this dependency is bypassed by active 
tyrosine kinases. Therefore, the Ba/F3 cell line is a standard cell culture model to determine 
activity and drug-mediated inhibition of tyrosine kinases (42). Accordingly, stable 
transfection of RET/C634R, RET/M918T and CCDC6-RET oncoproteins promotes IL-3-
independent growth (Fig. 5). Treatment with NPA101.3 blunted RET-driven (IC50 of 1.6-3.1 
nM), but not IL-3-driven parental Ba/F3 cell proliferation (Fig. 5), parallel to inhibition of 
RET phosphorylation (Supplementary information Fig. S4). 
 NPA101.3 inhibited proliferation of RET mutant TT, MZ-CRC-1, TPC-1 and Lc-2/ad 
human cancer cells with an IC50 of 0.67-3.6 nM (Supplementary information, Fig. S5 and 
Table S2). The IC50 dose for all human RET-negative cells was greater than 100.0 nM, 
confirming compound selectivity (Supplementary information, Fig. S6 and Table S2).  
	
NPA101.3 inhibits tumorigenicity of RET-transformed cells. The IC50 dose for NPA101.3-
mediated NIH3T3 RET/C634Y cell proliferation inhibition was 4.17 nM; virtually no effect 
was observed on proliferation of NIH3T3 HRAS/G12V cells up to 100.0 nM (Supplementary 
information Fig. S7). At 10.0 nM, the compound almost completely inhibited phosphorylation 
of RET and SHC, and attenuated phosphorylation of MAPK, in NIH3T3 RET/C634Y cells, 
while virtually no effect was detectable in NIH3T3 HRAS/G12V cells up to a dose of 100.0 
nM (Supplementary information Fig. S8). 
 In vivo target (RET and VEGFR2) inhibition was studied by treating animals grafted 
with NIH3T3 RET/C634Y cells at different doses (0.3, 1 or 3 mg/kg/day p.o.) of NPA101.3 
for two days and then performing Western blot analysis on protein extracts. As shown in 
Supplementary Fig. S9, 3 mg/kg/day dose of NPA101.3 strongly inhibited RET 
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autophosphorylation and signalling as well as VEGFR2 phosphorylation. Then, in order to 
determine anti-tumorigenic activity and to better distinguish RET- and VEGFR2-mediated 
effects, we tested NPA101.3 in nude mice transplanted with NIH3T3 cells transformed either 
by RET/C634Y or HRAS/G12V. Before tumours appeared, animals were treated daily with 
NPA101.3 (1.0, 3.0 or 10.0 mg/kg/day) or left untreated. NPA101.3 preferentially inhibited 
RET compared to RAS-driven tumours. While 10.0 mg/kg of compound completely 
prevented tumour formation induced by oncogenic RET, the treatment reduced, but did not 
abrogate, formation of tumours driven by RAS; moreover, at lower doses the compound 
significantly reduced growth of RET-, but not RAS-, driven tumors (Fig. 6). At 1.0 mg/kg, 
NPA101.3 exhibited strong RET phosphorylation and signalling inhibition in NIH3T3 
RET/C634Y tumours (Supplementary information Fig. S10); in contrast, virtually no effect 
on RAS signalling (MAPK phosphorylation) was detected in NIH3T3 HRAS/G12V tumours. 
Still, VEGFR2 inhibition was detected also in RAS-driven tumours, an effect that may explain 
the, albeit reduced, drug effect on their growth (Supplementary information Fig. S11). 
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DISCUSSION AND CONCLUSIONS 
Drug efficacy of a clinical agent is determined by target inhibition and ADMET (adsorption, 
distribution, metabolism, excretion, and toxicity) profiles (32). During the IND study of the 
clinical TKI candidate Pz-1, we identified a major, metabolic pathway initiated by Phase 1 
demethylation of the Pz-1 methylpyrazole substituent. Here, in order to generate secondary 
candidates with similar pharmacological profiles to Pz-1 but no propensity to demethylation, 
we replaced methylpyrazole with the metabolically-resistant bioisostere 
(methylsulfonyl)benzene. This lead to NPA101.3, a demethylation-resistant clinical candidate 
optimized for single-agent polypharmacology.  
Molecular modelling indicated that, similar to Pz-1, NPA101.3 binds the DFG-out 
‘inactive’ conformation of RET and VEGFR2, thus functioning as a bona fide type-2 TKI 
(31). This is supported experimentally by the relatively large thermal shift observed for the 
RET kinase-NPA101.3 complex. NPA101.3 exhibited an IC50 of 0.001 µM for RET and 0.003 
µM for VEGFR2. Noteworthy, similar to Pz-1, NPA101.3 was able to bind tightly to and 
inhibit (IC50 of 0.008 µM) the RET mutant at the gatekeeper site (V804M), which is refractory 
to the clinical inhibitors Vandetanib and Cabozantinib (31). NPA101.3 featured excellent 
selectivity for RET and VEGFR2, exhibiting affinity only for few other kinases such as TRKs 
(TRKA and TRKC), CSF1R, FRK, HCK, LYN and MKNK2. Among them, TRKA and 
TRKC are well known driver oncogenes, which expands the potential therapeutic application 
of NPA101.3 beyond RET-driven cancers (43). 
 In cell-based assays, NPA101.3 inhibited RET autophosphorylation and displayed a 
potent (IC50 between 0.67 and 4.17 nM) growth inhibitory effect on different types of RET 
(either transfected or endogenously expressing) mutant cells with no detectable effect at doses 
up to 100 nM in cells negative for RET oncogenes. Finally, NPA101.3 featured efficacy 
already at 1 mg/kg/day in RET-driven tumours in nude mice. At higher doses (10 mg/kg/day), 
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NPA101.3 displayed activity also against RAS-driven tumours, likely mediated by VEGFR2 
inhibition. Therefore, it is feasible that in a therapeutic setting against RET-driven tumours, 
activity of the compound may result from a combination of cell autonomous (on tumour cells 
growth mediated by RET inhibition) and non-cell autonomous (on blood vessels formation 
mediated by VEGFR2 inhibition) effects.  
Several TKIs with anti-RET activity are available and some are already registered for 
treatment of different types of thyroid cancers. Lesson learned from the use of TKIs in various 
cancer types has shown that second line inhibitors are clinically useful when first line 
treatments are hampered by toxicity and/or resistance. Based on potency, selectivity, and 
balanced RET/VEGFR2 inhibition, we posit that NPA101.3 may represent a promising, 
demethylation-resistant type-2 TKI for the treatment of RET-driven tumours.  
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EXPERIMENTAL SECTION  
 
General chemistry procedures and synthesis of NPA101.3. Molecular formula Smiles 
String:(O=C(NC1=NOC(C(C)(C)C)=C1)CC(C=C2)=CC=C2N(C=N3)C4=C3C=C(C5=CC
=C(S(=O)(C)=O)C=C5)C=C4) All solvents were reagent grade or HPLC grade and all 
starting materials were obtained from commercial sources and used without further 
purification. Purity of final compounds was assessed using a Shimadzu ultra-high throughput 
LC/MS system (SIL-20A, LC-20AD, LC-MS 2020, Phenomenex® Onyx Monolithic C-18 
Column) at variable wavelengths of 254 nM and 214 nM (Shimadzu PDA Detector, SPD-
MN20A) and was >95%, unless otherwise noted. The HPLC mobile phase consisted of a 
water-acetonitrile gradient buffered with 0.1% formic acid. 1H NMR spectra were recorded 
at 400 MHz and 13C spectra were recorded at 100 MHz, both completed on a Varian 400 
MHz instrument (Model# 4001S41ASP). All compounds were purified using silica gel 
(0.035-0.070 mm, 60 Å) flash chromatography, unless otherwise noted. Microwave assisted 
reactions were completed in sealed vessels using a Biotage Initiator microwave synthesizer. 
 
RET kinase assay. Kinase activity was measured by a microfluidic assay that monitors the 
separation of the phosphorylated product from substrate (31). The assay was run using a 12-
sipper chip on a Caliper EZ Reader II (PerkinElmer®, Walthman, USA) with separation buffer 
(100 mM HEPES, 10 mM EDTA, 0.015% Brij-35, 0.1% CR-3 PerkinElmer®). In 96-well 
polypropylene plates (Greiner, Frickenhausen, Germany), compound stocks (20 mM in 
DMSO) were diluted into kinase buffer (50 mM HEPES, 0.075% Brij-35, 0.1 % Tween 20, 2 
mM DTT, 10 mM MgCl2, and 0.02% NaN3) in 12-point ½log dilutions (2 mM–6.32 nM). 
After, 1 μL was transferred into a 384-well polypropylene assay plate (Greiner). The enzymes 
(Invitrogen™, Grand Island, USA) were diluted in kinase buffer to a concentration of 2 nM 
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and 5 µL of the enzyme mixture was transferred to the assay plate. RET, RET/V804M, or 
VEGFR2 kinases were pre-incubated with the TKI or control buffer, with gentle shaking for 
60 min to allow the inhibitor to trap the DFG-out conformation; indeed, it has been reported 
for the type-2 (DFG-out) p38 inhibitor, BIRB-796, that an increase in incubation time 
increases activity (44). A substrate mix was prepared containing ATP (Ambresco®, Solon, 
USA) and substrate peptide dissolved in kinase buffer, and 5 µL of the substrate mix was 
added to the assay plate. Running concentrations were as follows: ATP (190 µM), peptide 
(1.5 µM), compound 12-point ½log dilutions (0.2 mM–0.632 nM). For positive control, no 
inhibitor was added. For negative control, no enzyme was added. The plate was run until 10-
20% conversion, based on the positive control wells. The following separation conditions 
were utilized: upstream voltage -500V; downstream voltage, -1900V; chip pressure -0.8. 
Percent inhibition was measured for each well comparing starting peptide to phosphorylated 
product peaks relative to the baseline. Dose response curves, spanning the IC50 dose, were 
generated in GraphPad Prism® 7 and fit to an exponential one-phase decay line; IC50 values 
were obtained from the half-life value of the curve. IC50 values were generated in triplicate. 
 
Thermal shift assay. Wild type and V804M mutant RET core kinase domain proteins were 
expressed in SF21 cells and purified using a GST affinity tag as previously described (45). 
Subsequently, both proteins were purified and phosphorylated. The affinity tag was removed 
using HRV 3C protease. To determine the protein thermal shifts, 3µM recombinant proteins 
were incubated with DMSO (vehicle control), NPA101.3, PP1 or Sorafenib (in 100% DMSO), 
with a final drug concentration of 40µM, and a final DMSO concentration of 1% (v/v). Sypro-
Orange dye (Life Technologies) was added to each drug treatment, and the thermal shift was 
measured in a QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems) over a 
 16 
temperature range of 25–90 °C. Subsequent analysis was performed using Protein Thermal 
Shift Software v1.2 (Applied Biosystems).  
 
Cell cultures. NPA101.3 was dissolved in dimethyl sulfoxide (DMSO) at 50 mM 
concentration and stored at -80°C. Final dosing solution was prepared on the day of use by 
dilution of the stock solution in cell growth media. RAT1 cells transformed by the various 
RET mutants (46) were a kind gift of M. Billaud and were cultured in DMEM with 10% foetal 
calf serum, 2 mM L-glutamine and 100 units/ml penicillin-streptomycin (GIBCO). NIH3T3 
cells transformed by RET/C634Y, HRAS/G12V, CCDC6-RET, NCOA4-RET and 
FGFR1OP-RET were cultured in DMEM with 5% calf serum, 2 mM L-glutamine and 100 
units/mL penicillin-streptomycin (GIBCO). Parental NIH3T3 cells were grown in DMEM 
with 10% calf serum, 2 mM L-glutamine and 100 units/mL penicillin-streptomycin (GIBCO). 
All the RET constructs expressed in RAT1 or NIH3T3 cells encoded the short isoform of the 
RET protein (RET-9). Ba/F3 murine pro-B cells stably expressing NCOA4-RET, RET/C634R 
and RET/M918T mutant proteins (all cloned in the long RET-51 isoform) were generated by 
electroporation. Parental and transformed Ba/F3 cells were cultured in RPMI supplemented 
with 10% foetal calf serum, 2 mM L-glutamine and 100 units/ml penicillin-streptomycin 
(GIBCO), and, in the case of parental cells, supplemented with 10 ng/ml IL-3. CALU-1, 
derived from a human lung adenocarcinoma, were grown in EMEM with 10% foetal calf 
serum, 2 mM L-glutamine and 100 units/mL penicillin-streptomycin (GIBCO). PC-9, derived 
from a human lung adenocarcinoma, were grown in RPMI with 10% foetal calf serum, 2 mM 
L-glutamine and 100 units/mL penicillin-streptomycin. Nthy-ori-3-1, derived from normal 
thyroid follicular tissue and immortalized by SV40 Large T, TPC-1, derived from a human 
PTC harbouring CCDC6-RET (47), BCPAP, derived from human PTC, 8505-C, derived from 
a human undifferentiated thyroid cancer, and A549, derived from a human lung 
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adenocarcinoma, were cultured in DMEM with 10% foetal calf serum, 2 mM L-glutamine and 
100 units/mL penicillin-streptomycin. TT, from a human MTC harbouring RET/C634W (48), 
and MZ-CRC-1, from a human MTC harbouring RET/M918T (a kind gift of R. F. Gagel), 
were cultured in RPMI with 20% foetal calf serum, 2 mM L-glutamine and 100 units/mL 
penicillin-streptomycin (GIBCO). Lc-2/ad, derived from human lung adenocarcinoma 
harbouring CCDC6-RET (49), were grown in RPMI 1640/Ham's F12 (1:1) with 10% foetal 
calf serum, 2 mM L-glutamine and 100 units/mL penicillin-streptomycin (GIBCO). All the 
human cell lines were SNP authenticated in 2017. 
 
Immunoblotting. Protein lysates were prepared according to standard procedures. Briefly, 
cells were lysed in a buffer containing 50 mM N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid (HEPES; pH 7.5), 1% (vol/vol) Triton X-100, 150 mM NaCl, 5 mM 
EGTA, 50 mM NaF, 20 mM sodium pyrophosphate, 1 mM sodium vanadate, 2 mM 
phenylmethylsulphonyl fluoride (PMSF) and 1 µg/mL aprotinin. Lysates were clarified by 
centrifugation at 10,000 Xg for 15 min. Lysates containing comparable amounts of proteins, 
estimated by a modified Bradford assay (Bio-Rad, Munich, Germany), were subjected to 
direct Western blot. Immune complexes were detected with the enhanced chemiluminescence 
kit (Amersham Pharmacia Biotech, Little Chalfort, UK). Anti-phospho-SHC (#Y317), that 
recognizes SHC protein when phosphorylated on Y317, was from Upstate Biotechnology Inc. 
(Lake Placid, NY). Anti-SHC (H-108) was from Santa Cruz Biotechnology (Santa Cruz, CA). 
Anti-MAPK (#9101) and anti-phospho-MAPK (#9102), specific for p42/44MAPK (ERK1/2) 
phosphorylated on Thr202/Tyr204, were from Cell Signalling (Danvers, MA, USA). Anti-
phospho-VEGFR2/KDR (#2478), specific for VEGFR2/KDR phosphorylated on Tyr1175 
and anti-VEGFR2/KDR (#2479) were from Cell Signalling Technologies (Danvers, MA, 
USA). Anti-phospho-p70S6K (#9234), specific for p70S6K phosphorylated on Thr389 and 
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anti-p70S6K (#2708) were from Cell Signalling Technologies (Danvers, MA, USA). Anti-
RET is a polyclonal antibody raised against the tyrosine kinase protein fragment of human 
RET; anti-phospho905 is a phospho-specific polyclonal antibody recognizing RET proteins 
phosphorylated at Y905 and anti-phospho1062 is a phospho-specific polyclonal antibody 
recognizing RET proteins phosphorylated at Y1062 (50). Secondary antibodies coupled to 
horseradish peroxidase were from Santa Cruz Biotechnology.  
 
Cell growth curves. Nthy-ory-3-1 (10,000/well), TPC-1 (10,000/well), MZ-CRC-1 
(100,000/well), TT (200,000/well), Lc-2/ad (100,000/well), BCPAP (10,000/well), 8505-C 
(10,000/well), PC-9 (10,000/well), A549 (10,000/well), CALU-1 (10,000/well), NIH3T3 
RET/C634Y (10,000/well) and NIH3T3 HRAS/G12V (10,000/well) were seeded in 6-well 
tissue culture plates. Cells were kept in 2% (TPC-1), 5% (Nthy-ori-3-1), or 10% (BCPAP, 
8505-C, CALU-1, A549, PC-9, TT, MZ-CRC-1 and Lc-2/ad) foetal calf serum or in 2% 
(NIH3T3 RET/C634Y and HRAS/G12V) calf serum. Ba/F3 cells (200,000/well in 2ml) were 
seeded in 6-well tissue culture plates and kept in 10% foetal calf serum. The day after plating, 
different concentrations of drug or vehicle were added to the medium and changed every 2-3 
days. Cells were counted every day (Ba/F3), 2 days (fibroblasts) or 2-3 days (human cell 
lines). To compare cell growth, we performed unpaired Student’s t test using the Instat 
software program (Graphpad Software Inc). All P values were two-sided, and differences 
were considered statistically significant at P <.02. IC50 doses were calculated through a curve 
fitting analysis from last day of growth curves using the PRISM software program (Graphpad 
Software Inc). 
 
Mouse xenograft experiments. NPA101.3 was dissolved in 80% H2O, 19.875% Tween 20, 
0.125% Xanthan gum. The formulation was stored at room temperature and vortexed prior to 
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administration. NIH3T3 RET/C634Y (200,000 cells) or NIH3T3 HRAS/G12V (50,000 cells) 
were inoculated subcutaneously into dorsal portion (both sides) of 6-week-old female BALB/c 
nu/nu mice (n. 32 mice/cell line) (Jackson Laboratories, Bar Harbor, Maine). After 4 days, 
before tumours had appeared, animals were randomly assigned to receive NPA101.3 (1.0, 3.0 
or 10 mg/kg daily) (8 mice/group) or vehicle control (8 mice) by oral gavage. Tumour 
diameters were measured with caliper every 2-3 days. Tumour volumes (V) were calculated 
by the rotational ellipsoid formula: V= A x B2/2 (A=axial diameter; B= rotational diameter). 
No mouse showed signs of wasting or other signs of toxicity. Animals were fed ad libitum on 
an autoclaved diet and tap water and were maintained at the Dipartimento di Medicina 
Molecolare e Biotecnologie Mediche Animal Facility. All manipulations were performed 
while the animals were under isoflurane gas anaesthesia. Animal studies were conducted in 
accordance with Italian regulations for experimentation on animals and approved by the 
Italian Ministry of health (Authorization n. 1023/2015-PR). To compare tumour growth the 
unpaired Student’s t test (InStat program, GraphPad software) was used. P values were 
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Figure 1: Metabolism of Pz-1 and Bioisosteric Replacement Methods ¾ Pz-1 is 
hydrolyzed, oxidized, or demethylated via Phase 1 metabolic systems. Hydrolysis and 
oxidation occur in the selectivity region for binding to RET and VEGFR2, while 
demethylation occurs at the solvent front for both kinases. Bioisosteric replacement at the 
solvent front was performed by replacing methylpyrazole with (methylsulfonyl)benzene, 
generating NPA101.3. VEGFR2 DFG-out crystal structure (PDB# 2OH4); RET DFG-out 





Figure 2: Computational modelling of NPA101.3 ¾ (A) NPA101.3 computationally 
modelled in a RET DFG-out homology model. The model shows the hydrogen bond at the 
ATP binding site with A807, a hydrogen bond network at the DFG motif, and interaction with 
Y806 via π-π stacking. The model also shows that p-sulfone of NPA101.3 is solvent exposed. 
Hydrogen bonds are shown with blue dotted lines. (B) NPA101.3 computationally modelled 
in a RET/V804M DFG-out homology model. NPA101.3 is able to accommodate bulky 
mutations at the gatekeeper residue. (C) NPA101.3 computationally modelled in the VEGFR2 
kinase. The binding mode is near identical to the binding in RET, with exception of the 
isoxazole orientation in the allosteric pocket. Flexibility at the methylene linker is predicted 






Figure 3: Thermal shift assay determination of the type-2 binding mode of NPA101.3 ¾ 
(A) Representative experiment of binding of NPA101.3 to wild type RET core kinase domain 
monitored by the change in thermal stability. The melting temperature Tm is obtained from 
the first derivative of the change in fluorescence (-dF/dt) taken from the top of the peak in the 
derivative plot. (B) Plot of the derivative of the change in fluorescence (-dF/dt) for the wild 
type protein or V804M mutant in the presence of NPA101.3 or buffer for a representative 
experiment. The compound binds equally well to either RET protein (C) Tabulated average 
melting temperature differences (DTm) from four independent experiments after addition of 
NPA101.3, PP1 (a known type-1 inhibitor) or Sorafenib (a known type-2 inhibitor). The 






Figure 4: NPA101.3-mediated inhibition of phosphorylation and signalling of oncogenic 
RET mutants and VEGFR2 in intact cells ¾ Serum-starved RAT1 cells exogenously 
expressing the indicated RET point mutants (A, B) or NIH3T3 cells exogenously expressing 
the indicated RET rearranged mutants (C) were treated for 2 hr with indicated concentrations 
of compound. Total cell lysates (50 µg) were subjected to immunoblotting with anti-phospho-
Y1062 (ap1062) and anti-phospho-Y905 (ap905) RET antibodies. The blots were normalized 
using anti-RET (aRET) antibody. D) HEK293 cells were transiently transfected with human 
VEGFR2; 36 hr after transfection, cells were serum starved for 12 hr. The indicated doses of 
compound or vehicle (NT) were added for 2 hr and then VEGFA (100 ng/ml) stimulation was 
applied for 15 min. Cell lysates were immunoblotted with anti-phospho-VEGFR2 






Figure 5: NPA101.3-mediated inhibition of proliferation of RET-transformed Ba/F3 
cells ¾ Parental and RET/C634R, RET M918T and NCOA4-RET transfected Ba/F3 cells 
were incubated with vehicle (NT: not treated) or the indicated concentrations of NPA101.3 
and counted at the indicated time points. Parental cells were supplemented with IL3 (10 
ng/ml). Data are the mean ± SD of a single experiment performed in triplicate. Growth 
inhibition IC50 doses of the compound for the different cell lines are reported. 95% CI are 







Figure 6: Effects of NPA101.3 on in vivo tumour growth ¾ NIH3T3 cells transformed by 
RET/C634Y or HRAS/G12V were inoculated subcutaneously into nu/nu mice. After 4 days, 
animals were randomly assigned to receive for the indicated time periods the compound (1.0, 
3.0 or 10 mg/kg daily) (24 mice: 8 mice/group for 1, 3 and 10 mg/kg doses) or vehicle (8 
mice) by oral gavage. Average size of tumors is reported ± SD.  
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